Why COVID vaccines are so difficult to compare Despite the widespread roll-out of several vaccines, it could be months before they can be ranked. Heidi Ledford nature

Yusuff Adebayo Adebisi knows that a vaccine that offers 70% protection against COVID-19 could be a valuable tool against the coronavirus pandemic in Nigeria — especially if that vaccine is cheap and doesn’t have to be stored at extremely cold temperatures. But what if another vaccine — one that is more expensive to buy and to store — was 95% effective?

A national health care provider has administered COVID-19 vaccinations to people deemed ineligible for the scarce vaccine by local health departments, including people with connections to company leaders and customers of its concierge medical service, according to internal communications leaked to NPR.

Germany approves COVID home tests to ease way out of lockdown Germany approved three COVID-19 tests for home use as part Health Minister Jens Spahn's strategy to help Europe's biggest economy emerge from a lockdown that has been in place since mid-December. Reuters Staff U.S.

BERLIN (Reuters) - Germany approved three COVID-19 tests for home use as part Health Minister Jens Spahn’s strategy to help Europe’s biggest economy emerge from a lockdown that has been in place since mid-December.

What we know about California COVID variant B.1.427/ B.1.429 Researchers from the University of California, San Francisco, say it should be listed as a "variant of concern." Newsweek

A new coronavirus variant that was first identified in California is now taking hold in some parts of the state—but what do we currently know about it?

The variant actually comes in two forms, known as B.1.427 and B.1.429, both of which carry a similar, albeit slightly differing, set of genetic mutations—including three that affect the spike protein of the SARS-CoV-2 virus.

FDA says J&J 1-dose shot prevents COVID; final decision soon

WASHINGTON (AP) — Johnson & Johnson’s single-dose vaccine protects against COVID-19, according to an analysis by U.S. regulators Wednesday that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic.

As vaccine production ramps up, the White House announced the weekly supply for states will again increase 

(New York Times) The White House said on Tuesday that weekly shipments of coronavirus vaccines to the states would rise by one million doses to 14.5 million, as vaccine manufacturers continue to ramp up production.

The figure was provided to governors in a call with Jeffrey Zeints, the president’s coronavirus response coordinator, said Jen Psaki, the White House press secretary, on Tuesday. With tens of millions of eligible Americans waiting to get shots, state officials have been clamoring for more vaccine, saying health practitioners could easily double or triple the number of shots they are administering.

Drug executives: Big jump in vaccine supply is coming soon

WASHINGTON (AP) — COVID-19 vaccine makers told Congress on Tuesday to expect a big jump in the delivery of doses over the coming month, and the companies insist they will be able to provide enough for most Americans to get inoculated by summer.

By the end of March, Pfizer and Moderna expect to have provided the U.S. government with a total of 220 million vaccine doses, up sharply from the roughly 75 million shipped so far.

“We do believe we’re on track,” Moderna President Stephen Hoge said, outlining ways the company has ramped up production. “We think we’re at a very good spot.”

Researchers still investigating loss of smell problems among some of Covid victims

 ... A year into the coronavirus pandemic, doctors and researchers are still striving to better understand and treat the accompanying epidemic of COVID-19-related anosmia — loss of smell — draining much of the joy of life from an increasing number of sensorially frustrated longer-term sufferers like Forgione.

Even specialist doctors say there is much about the condition they still don’t know and they are learning as they go along in their diagnoses and treatments. Impairment and alteration of smell have become so common with COVID-19 that some researchers suggest that simple odor tests could be used to track coronavirus infections in countries with few laboratories.

Dozens of institutional investors push for 'equitable' Covid-19 response “The economic and financial damage triggered by Covid-19 knows no border,” said Marco Morelli, executive chairman of AXA Investment Managers. Ed Silverman STAT

Nearly 150 institutional investors that oversee combined assets worth more than $14 trillion have issued a joint call for a “fair and equitable” global response to the Covid-19 pandemic, and they intend to huddle with health care companies to make progress on that goal.